Most patients use semaglutide for at least 3 to 6 months , while others continue for longer periods to maintain results
Despite lifestyle interventions forming the cornerstone of therapy, long-term weight loss is difficult to sustain for many individuals, leading to growing interest in pharmacological options
Cross-trial scans favor tirzepatide: semaglutide measured about 62:38 fat-to-lean loss versus roughly 75:25 for tirzepatide. The scan overstates muscle loss, however, because lean mass includes water and organs
$47.59 $67.98 Rejuvenzyme $47.59 Rejuvenzyme On Sale
up to 1.8%) and body weight compared with placebo and several active treatments, including sitagliptin, exenatide (extended-release), dulaglutide, and insulin glargine.In the SUSTAIN 6 trial, semaglutide also demonstrated CV safety and significantly reduced MACE compared with placebo, confirming its noninferiority while suggesting potential CV protection.[9] 5
Any such tools found online are unvalidated and unsafe